Latest news

• AZ’s BTK inhibitor Calquence fails in COVID-19 study

  The CALAVI phase 2 trials had been evaluating the efficacy and safety of Calquence (acalabrutinib) alongside best supportive care (BCS) in patients hospitalised with respiratory complications of COVID-19.

• AZ strengthens Daiichi Sankyo partnership with new ADC deal

  acalabrutinib) and its recently approved, Daiichi-partnered HER2-targeting ADC, Enhertu (trastuzumab deruxtecan).

• GSK’s anti-BCMA drug leads crowded CHMP recommendations

  AstraZeneca also received two positive opinions following the meeting, with a recommendation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia and a label extension of its PD-1 inhibitor Imfinzi (durvalumab)

• AZ revenues rise, but it says coronavirus could hit 2020

  Recently-approved for a new chronic lymphocytic leukaemia (CLL) indication, AZ’s rival to Johnson &Johnson’s blockbuster BTK inhibitor Imbruvica (ibrutinib) – Calquence (acalabrutinib) – also gathered momentum and contributed $56m in

• EMA begins review of Kite’s CAR-T for mantle cell lymphoma

  Current treatment options for MCL include AstraZeneca’s BTK inhibitor  Calquence (acalabrutinib) and Johnson &Johnson/AbbVie’s BTK inhibitor Imbruvica (ibrutinib).